Endocytotic Uptake of Zoledronic Acid by Tubular Cells May Explain Its Renal Effects in Cancer Patients Receiving High Doses of the Compound

Zoledronic acid, a highly potent nitrogen-containing bisphosphonate used for the treatment of pathological bone loss, is excreted unmetabolized via the kidney if not bound to the bone. In cancer patients receiving high doses of the compound renal excretion may be associated with acute tubular necros...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhulst, Anja, Sun, Shuting, McKenna, Charles E., D’Haese, Patrick C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355483/
https://www.ncbi.nlm.nih.gov/pubmed/25756736
http://dx.doi.org/10.1371/journal.pone.0121861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355483/
https://www.ncbi.nlm.nih.gov/pubmed/25756736
http://dx.doi.org/10.1371/journal.pone.0121861

Ejemplares similares